Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)

BackgroundLow-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality....

Full description

Bibliographic Details
Main Authors: Isabella Sudano, Francois Mach, Tiziano Moccetti, Thilo Burkard, Christian Fahe, Alain Delabays, Hans Rickli, Pierre-Frédéric Keller, Jörn Dopheide, Sereina Bodenmann, Tom Fiolka, Georg Ehret, David Spirk
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
atherosclerotic cardiovascular disease
heterozygous familial hypercholesterolemia
LDL-C target attainment
PCSK9 inhibition
statin intolerance
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.953040/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.953040/full

Similar Items